Advertisement

MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder

      Highlights

      • MOG antibody disease is the most recent antigen specific autoimmune disease on the NMO Spectrum.
      • MOG antibody disease is characterized by optic neuritis and less commonly transverse myelitis with generally better outcomes compared to the AQP4 NMO.
      • Half of MOG antibody positive cases remain monophasic after the initial attack.

      Abstract

      MOG antibody disease is an autoimmune disease of the central nervous system associated with a serological antibody against MOG, myelin oligodendrocyte glycoprotein. MOG is a glycoprotein expressed on the outer membrane of myelin and solely found within the central nervous system, including in the brain, optic nerves and spinal cord. Clinically, the disease resembles neuromyelitis optica spectrum disorders in the predilection for relapses of optic neuritis and transverse myelitis. In addition, acute disseminated encephalomyelitis (ADEM) is a well-recognized phenotype of MOG antibody disease in children. In recent studies around the world where MOG testing is available, up to 42% of NMOSD patients who test seronegative for the AQP4 antibody test positive for MOG antibodies. MOG antibody disease has thus recently emerged as a distinct entity carved out of the patient population diagnosed with NMOSD. In this review, we examine the history of the MOG antibody and its relevance to demyelinating disease, as well as compare the clinical, radiographic and serological profiles of patients with MOG antibody with patients with AQP4 antibody.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Akaishi T.
        • Sato D.K.
        • Nakashima I.
        • Takeshita T.
        • Takahashi T.
        • Doi H.
        • Kurosawa K.
        • Kaneko K.
        • Kuroda H.
        • Nishiyama S.
        • Misu T.
        • Nakazawa T.
        • Fujihara K.
        • Aoki M.
        MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study.
        J. Neurol. Neurosurg. Psychiatry. 2016; 87: 446-448
        • Baumann M.
        • Sahin K.
        • Lechner C.
        • Hennes E.M.
        • Schanda K.
        • Mader S.
        • Karenfort M.
        • Selch C.
        • Hausler M.
        • Eisenkolbl A.
        • Salandin M.
        • Gruber-Sedlmayr U.
        • Blaschek A.
        • Kraus V.
        • Leiz S.
        • Finsterwalder J.
        • Gotwald T.
        • Kuchukhidze G.
        • Berger T.
        • Reindl M.
        • Rostasy K.
        Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein.
        J. Neurol. Neurosurg. Psychiatry. 2015; 86: 265-272
        • Berger T.
        • Rubner P.
        • Schautzer F.
        • Egg R.
        • Ulmer H.
        • Mayringer I.
        • Dilitz E.
        • Deisenhammer F.
        • Reindl M.
        Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.
        N. Engl. J. Med. 2003; 349: 139-145
        • Brilot F.
        • Dale R.C.
        • Selter R.C.
        • Grummel V.
        • Kalluri S.R.
        • Aslam M.
        • Busch V.
        • Zhou D.
        • Cepok S.
        • Hemmer B.
        Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease.
        Ann. Neurol. 2009; 66: 833-842
        • Brunner C.
        • Lassmann H.
        • Waehneldt T.V.
        • Matthieu J.M.
        • Linington C.
        Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2′,3′-cyclic nucleotide 3′-phosphodiesterase in the CNS of adult rats.
        J. Neurochem. 1989; 52: 296-304
        • Chalmoukou K.
        • Alexopoulos H.
        • Akrivou S.
        • Stathopoulos P.
        • Reindl M.
        • Dalakas M.C.
        Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis.
        Neurol. Neuroimmunol. Neuroinflamm. 2015; 2: e131
        • Chen H.X.
        • Zhang Q.
        • Lian Z.Y.
        • Liu J.
        • Shi Z.Y.
        • Miao X.H.
        • Feng H.R.
        • Du Q.
        • Xie J.L.
        • Yao S.L.
        • Zhou H.Y.
        Muscle damage in patients with neuromyelitis optica spectrum disorder.
        Neurol. Neuroimmunol. Neuroinflamm. 2017; 4: e400
        • Dale R.C.
        • Tantsis E.M.
        • Merheb V.
        • Kumaran R.Y.
        • Sinmaz N.
        • Pathmanandavel K.
        • Ramanathan S.
        • Booth D.R.
        • Wienholt L.A.
        • Prelog K.
        • Clark D.R.
        • Guillemin G.J.
        • Lim C.K.
        • Mathey E.K.
        • Brilot F.
        Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton.
        Neurol. Neuroimmunol. Neuroinflamm. 2014; 1: e12
        • Di Pauli F.
        • Hoftberger R.
        • Reindl M.
        • Beer R.
        • Rhomberg P.
        • Schanda K.
        • Sato D.
        • Fujihara K.
        • Lassmann H.
        • Schmutzhard E.
        • Berger T.
        Fulminant demyelinating encephalomyelitis: insights from antibody studies and neuropathology.
        Neurol. Neuroimmunol. Neuroinflamm. 2015; 2: e175
        • Hacohen Y.
        • Wong Y.Y.
        • Lechner C.
        • Jurynczyk M.
        • Wright S.
        • Konuskan B.
        • Kalser J.
        • Poulat A.L.
        • Maurey H.
        • Ganelin-Cohen E.
        • Wassmer E.
        • Hemingway C.
        • Forsyth R.
        • Hennes E.M.
        • Leite M.I.
        • Ciccarelli O.
        • Anlar B.
        • Hintzen R.
        • Marignier R.
        • Palace J.
        • Baumann M.
        • Rostasy K.
        • Neuteboom R.
        • Deiva K.
        • Lim M.
        Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.
        JAMA Neurol. 2018; 75: 478-487
        • Huppke P.
        • Rostasy K.
        • Karenfort M.
        • Huppke B.
        • Seidl R.
        • Leiz S.
        • Reindl M.
        • Gartner J.
        Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients.
        Multiple Scler. 2013; 19: 941-946
        • Hamid S.H.M.
        • Whittam D.
        • Mutch K.
        • Linaker S.
        • Solomon T.
        • Das K.
        • Bhojak M.
        • Jacob A.
        What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients.
        J. Neurol. 2017; 264: 2088-2094
        • Hamid S.H.M.
        • Whittam D.
        • Saviour M.
        • Alorainy A.
        • Mutch K.
        • Linaker S.
        • Solomon T.
        • Bhojak M.
        • Woodhall M.
        • Waters P.
        • Appleton R.
        • Duddy M.
        • Jacob A.
        Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs. aquaporin 4 IgG disease.
        JAMA Neurol. 2018; 75: 65-71
        • Havla J.
        • Kumpfel T.
        • Schinner R.
        • Spadaro M.
        • Schuh E.
        • Meinl E.
        • Hohlfeld R.
        • Outteryck O.
        Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
        J. Neurol. 2017; 264: 139-151
        • Huppke P.
        • Rostasy K.
        • Karenfort M.
        • Huppke B.
        • Seidl R.
        • Leiz S.
        • Reindl M.
        • Gartner J.
        Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients.
        Multiple Scler. 2013; 19: 941-946
        • Hyun J.W.
        • Woodhall M.R.
        • Kim S.H.
        • Jeong I.H.
        • Kong B.
        • Kim G.
        • Kim Y.
        • Park M.S.
        • Irani S.R.
        • Waters P.
        • Kim H.J.
        Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases.
        J. Neurol. Neurosurg. Psychiatry. 2017; 88: 811-817
        • Jarius S.
        • Kleiter I.
        • Ruprecht K.
        • Asgari N.
        • Pitarokoili K.
        • Borisow N.
        • Hummert M.W.
        • Trebst C.
        • Pache F.
        • Winkelmann A.
        • Beume L.A.
        • Ringelstein M.
        • Stich O.
        • Aktas O.
        • Korporal-Kuhnke M.
        • Schwarz A.
        • Lukas C.
        • Haas J.
        • Fechner K.
        • Buttmann M.
        • Bellmann-Strobl J.
        • Zimmermann H.
        • Brandt A.U.
        • Franciotta D.
        • Schanda K.
        • Paul F.
        • Reindl M.
        • Wildemann B.
        • in cooperation with the Neuromyelitis Optica Study, G.
        MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement - frequency, presentation and outcome.
        J. Neuroinflamm. 2016; 13: 281
        • Jarius S.
        • Metz I.
        • Konig F.B.
        • Ruprecht K.
        • Reindl M.
        • Paul F.
        • Bruck W.
        • Wildemann B.
        Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case.
        Multiple Scler. 2016; 22: 1541-1549
        • Jarius S.
        • Paul F.
        • Franciotta D.
        • Waters P.
        • Zipp F.
        • Hohlfeld R.
        • Vincent A.
        • Wildemann B.
        Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica.
        Nat. Clin. Pract. Neurol. 2008; 4: 202-214
        • Jarius S.
        • Ruprecht K.
        • Kleiter I.
        • Borisow N.
        • Asgari N.
        • Pitarokoili K.
        • Pache F.
        • Stich O.
        • Beume L.A.
        • Hummert M.W.
        • Ringelstein M.
        • Trebst C.
        • Winkelmann A.
        • Schwarz A.
        • Buttmann M.
        • Zimmermann H.
        • Kuchling J.
        • Franciotta D.
        • Capobianco M.
        • Siebert E.
        • Lukas C.
        • Korporal-Kuhnke M.
        • Haas J.
        • Fechner K.
        • Brandt A.U.
        • Schanda K.
        • Aktas O.
        • Paul F.
        • Reindl M.
        • Wildemann B.
        • in cooperation with the Neuromyelitis Optica Study, G.
        MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
        J. Neuroinflamm. 2016; 13: 280
        • Jarius S.
        • Ruprecht K.
        • Kleiter I.
        • Borisow N.
        • Asgari N.
        • Pitarokoili K.
        • Pache F.
        • Stich O.
        • Beume L.A.
        • Hummert M.W.
        • Trebst C.
        • Ringelstein M.
        • Aktas O.
        • Winkelmann A.
        • Buttmann M.
        • Schwarz A.
        • Zimmermann H.
        • Brandt A.U.
        • Franciotta D.
        • Capobianco M.
        • Kuchling J.
        • Haas J.
        • Korporal-Kuhnke M.
        • Lillevang S.T.
        • Fechner K.
        • Schanda K.
        • Paul F.
        • Wildemann B.
        • Reindl M.
        • in cooperation with the Neuromyelitis Optica Study, G.
        MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
        J. Neuroinflamm. 2016; 13: 279
        • Jarius S.
        • Ruprecht K.
        • Wildemann B.
        • Kuempfel T.
        • Ringelstein M.
        • Geis C.
        • Kleiter I.
        • Kleinschnitz C.
        • Berthele A.
        • Brettschneider J.
        • Hellwig K.
        • Hemmer B.
        • Linker R.A.
        • Lauda F.
        • Mayer C.A.
        • Tumani H.
        • Melms A.
        • Trebst C.
        • Stangel M.
        • Marziniak M.
        • Hoffmann F.
        • Schippling S.
        • Faiss J.H.
        • Neuhaus O.
        • Ettrich B.
        • Zentner C.
        • Guthke K.
        • Hofstadt-van Oy U.
        • Reuss R.
        • Pellkofer H.
        • Ziemann U.
        • Kern P.
        • Wandinger K.P.
        • Bergh F.T.
        • Boettcher T.
        • Langel S.
        • Liebetrau M.
        • Rommer P.S.
        • Niehaus S.
        • Munch C.
        • Winkelmann A.
        • Zettl U.U.
        • Metz I.
        • Veauthier C.
        • Sieb J.P.
        • Wilke C.
        • Hartung H.P.
        • Aktas O.
        • Paul F.
        Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients.
        J. Neuroinflamm. 2012; 9: 14
        • Jarius S.
        • Paul F.
        • Aktas O.
        • Asgari N.
        • Dale R.C.
        • de Seze J.
        • Franciotta D.
        • Fujihara K.
        • Jacob A.
        • Kim H.J.
        • Kleiter I.
        • Kümpfel T.
        • Levy M.
        • Palace J.
        • Ruprecht K.
        • Saiz A.
        • Trebst C.
        • Weinshenker B.G.
        • Wildemann B.
        MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.
        J. Neuroinflamm. 2018; 15: 134
        • Johns T.G.
        • Bernard C.C.
        The structure and function of myelin oligodendrocyte glycoprotein.
        J. Neurochem. 1999; 72: 1-9
        • Jurynczyk M.
        • Geraldes R.
        • Probert F.
        • Woodhall M.R.
        • Waters P.
        • Tackley G.
        • DeLuca G.
        • Chandratre S.
        • Leite M.I.
        • Vincent A.
        • Palace J.
        Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.
        Brain. 2017; 140: 617-627
        • Jurynczyk M.
        • Messina S.
        • Woodhall M.R.
        • Raza N.
        • Everett R.
        • Roca-Fernandez A.
        • Tackley G.
        • Hamid S.
        • Sheard A.
        • Reynolds G.
        • Chandratre S.
        • Hemingway C.
        • Jacob A.
        • Vincent A.
        • Leite M.I.
        • Waters P.
        • Palace J.
        Clinical presentation and prognosis in MOG-antibody disease: a UK study.
        Brain. 2017; 140: 3128-3138
        • Jurynczyk M.
        • Tackley G.
        • Kong Y.
        • Geraldes R.
        • Matthews L.
        • Woodhall M.
        • Waters P.
        • Kuker W.
        • Craner M.
        • Weir A.
        • DeLuca G.C.
        • Kremer S.
        • Leite M.I.
        • Vincent A.
        • Jacob A.
        • de Seze J.
        • Palace J.
        Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.
        J. Neurol. Neurosurg. Psychiatry. 2017; 88: 132-136
        • Kaneko K.
        • Sato D.K.
        • Nakashima I.
        • Nishiyama S.
        • Tanaka S.
        • Marignier R.
        • Hyun J.W.
        • Oliveira L.M.
        • Reindl M.
        • Seifert-Held T.
        • Sepulveda M.
        • Siritho S.
        • Waters P.J.
        • Kurosawa K.
        • Akaishi T.
        • Kuroda H.
        • Misu T.
        • Prayoonwiwat N.
        • Berger T.
        • Saiz A.
        • Kim H.J.
        • Nomura K.
        • Callegaro D.
        • Fujihara K.
        • Aoki M.
        Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies.
        J. Neurol. Neurosurg. Psychiatry. 2016; 87: 1257-1259
        • Kim H.J.
        • Paul F.
        • Lana-Peixoto M.A.
        • Tenembaum S.
        • Asgari N.
        • Palace J.
        • Klawiter E.C.
        • Sato D.K.
        • de Seze J.
        • Wuerfel J.
        • Banwell B.L.
        • Villoslada P.
        • Saiz A.
        • Fujihara K.
        • Kim S.H.
        • Guthy-Jackson Charitable Foundation, N.M.O.I.C.C., Biorepository
        MRI characteristics of neuromyelitis optica spectrum disorder: an international update.
        Neurology. 2015; 84: 1165-1173
        • Kim S.H.
        • Kim W.
        • Li X.F.
        • Jung I.J.
        • Kim H.J.
        Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
        Arch. Neurol. 2011; 68: 1412-1420
        • Kim S.M.
        • Woodhall M.R.
        • Kim J.S.
        • Kim S.J.
        • Park K.S.
        • Vincent A.
        • Lee K.W.
        • Waters P.
        Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS.
        Neurol. Neuroimmunol. Neuroinflamm. 2015; 2: e163
        • Kitley J.
        • Leite M.I.
        • Kuker W.
        • Quaghebeur G.
        • George J.
        • Waters P.
        • Woodhall M.
        • Vincent A.
        • Palace J.
        Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies.
        JAMA Neurol. 2013; 70: 1375-1381
        • Kitley J.
        • Waters P.
        • Woodhall M.
        • Leite M.I.
        • Murchison A.
        • George J.
        • Kuker W.
        • Chandratre S.
        • Vincent A.
        • Palace J.
        Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
        JAMA Neurol. 2014; 71: 276-283
        • Kiyat-Atamer A.
        • Ekizoglu E.
        • Tuzun E.
        • Kurtuncu M.
        • Shugaiv E.
        • Akman-Demir G.
        • Eraksoy M.
        Long-term MRI findings in neuromyelitis optica: seropositive versus seronegative patients.
        Eur. J. Neurol. 2013; 20: 781-787
        • Kremer L.
        • Mealy M.
        • Jacob A.
        • Nakashima I.
        • Cabre P.
        • Bigi S.
        • Paul F.
        • Jarius S.
        • Aktas O.
        • Elsone L.
        • Mutch K.
        • Levy M.
        • Takai Y.
        • Collongues N.
        • Banwell B.
        • Fujihara K.
        • de Seze J.
        Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients.
        Multiple Scler. 2014; 20: 843-847
        • Kuhle J.
        • Pohl C.
        • Mehling M.
        • Edan G.
        • Freedman M.S.
        • Hartung H.P.
        • Polman C.H.
        • Miller D.H.
        • Montalban X.
        • Barkhof F.
        • Bauer L.
        • Dahms S.
        • Lindberg R.
        • Kappos L.
        • Sandbrink R.
        Lack of association between antimyelin antibodies and progression to multiple sclerosis.
        N. Engl. J. Med. 2007; 356: 371-378
        • Lampasona V.
        • Franciotta D.
        • Furlan R.
        • Zanaboni S.
        • Fazio R.
        • Bonifacio E.
        • Comi G.
        • Martino G.
        Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects.
        Neurology. 2004; 62: 2092-2094
        • Lim E.T.
        • Berger T.
        • Reindl M.
        • Dalton C.M.
        • Fernando K.
        • Keir G.
        • Thompson E.J.
        • Miller D.H.
        • Giovannoni G.
        Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis.
        Multiple Scler. 2005; 11: 492-494
        • Mader S.
        • Gredler V.
        • Schanda K.
        • Rostasy K.
        • Dujmovic I.
        • Pfaller K.
        • Lutterotti A.
        • Jarius S.
        • Di Pauli F.
        • Kuenz B.
        • Ehling R.
        • Hegen H.
        • Deisenhammer F.
        • Aboul-Enein F.
        • Storch M.K.
        • Koson P.
        • Drulovic J.
        • Kristoferitsch W.
        • Berger T.
        • Reindl M.
        Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
        J. Neuroinflamm. 2011; 8: 184
        • Malik R.
        • Lewis A.
        • Cree B.A.
        • Ratelade J.
        • Rossi A.
        • Verkman A.S.
        • Bollen A.W.
        • Ralph J.W.
        Transient hyperckemia in the setting of neuromyelitis optica (NMO).
        Muscle Nerve. 2014; 50: 859-862
        • Mariotto S.
        • Ferrari S.
        • Monaco S.
        • Benedetti M.D.
        • Schanda K.
        • Alberti D.
        • Farinazzo A.
        • Capra R.
        • Mancinelli C.
        • De Rossi N.
        • Bombardi R.
        • Zuliani L.
        • Zoccarato M.
        • Tanel R.
        • Bonora A.
        • Turatti M.
        • Calabrese M.
        • Polo A.
        • Pavone A.
        • Grazian L.
        • Sechi G.
        • Sechi E.
        • Urso D.
        • Delogu R.
        • Janes F.
        • Deotto L.
        • Cadaldini M.
        • Bianchi M.R.
        • Cantalupo G.
        • Reindl M.
        • Gajofatto A.
        Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study.
        J. Neurol. 2017; 264: 2420-2430
        • Matiello M.
        • Lennon V.A.
        • Jacob A.
        • Pittock S.J.
        • Lucchinetti C.F.
        • Wingerchuk D.M.
        • Weinshenker B.G.
        NMO-IgG predicts the outcome of recurrent optic neuritis.
        Neurology. 2008; 70: 2197-2200
        • Mealy M.A.
        • Kim S.H.
        • Schmidt F.
        • Lopez R.
        • Jimenez Arango J.A.
        • Paul F.
        • D.M. Wingerchuk
        • B.M. Greenberg
        • Kim H.J.
        • Levy M.
        Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders.
        Multiple Scler. 2017; 1352458517730131
        • Misu T.
        • Hoftberger R.
        • Fujihara K.
        • Wimmer I.
        • Takai Y.
        • Nishiyama S.
        • Nakashima I.
        • Konno H.
        • Bradl M.
        • Garzuly F.
        • Itoyama Y.
        • Aoki M.
        • Lassmann H.
        Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica.
        Acta Neuropathol. 2013; 125: 815-827
        • Montcuquet A.
        • Collongues N.
        • Papeix C.
        • Zephir H.
        • Audoin B.
        • Laplaud D.
        • Bourre B.
        • Brochet B.
        • Camdessanche J.P.
        • Labauge P.
        • Moreau T.
        • Brassat D.
        • Stankoff B.
        • de Seze J.
        • Vukusic S.
        • Marignier R.
        • group, N.s., the Observatoire Francais de la Sclerose en, P.
        Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.
        Multiple Scler. 2017; 23: 1377-1384
        • Moura F.C.
        • Sato D.K.
        • Rimkus C.M.
        • Apostolos-Pereira S.L.
        • de Oliveira L.M.
        • Leite C.C.
        • Fujihara K.
        • Monteiro M.L.
        • Callegaro D.
        Anti-MOG (myelin oligodendrocyte glycoprotein)-positive severe optic neuritis with optic disc ischaemia and macular star.
        Neuroophthalmology. 2015; 39: 285-288
        • O'Connor K.C.
        • McLaughlin K.A.
        • De Jager P.L.
        • Chitnis T.
        • Bettelli E.
        • Xu C.
        • Robinson W.H.
        • Cherry S.V.
        • Bar-Or A.
        • Banwell B.
        • Fukaura H.
        • Fukazawa T.
        • Tenembaum S.
        • Wong S.J.
        • Tavakoli N.P.
        • Idrissova Z.
        • Viglietta V.
        • Rostasy K.
        • Pohl D.
        • Dale R.C.
        • Freedman M.
        • Steinman L.
        • Buckle G.J.
        • Kuchroo V.K.
        • Hafler D.A.
        • Wucherpfennig K.W.
        Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein.
        Nat. Med. 2007; 13: 211-217
        • Ogawa R.
        • Nakashima I.
        • Takahashi T.
        • Kaneko K.
        • Akaishi T.
        • Takai Y.
        • Sato D.K.
        • Nishiyama S.
        • Misu T.
        • Kuroda H.
        • Aoki M.
        • Fujihara K.
        MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy.
        Neurol. Neuroimmunol. Neuroinflamm. 2017; 4: e322
        • Oh J.
        • Levy M.
        Neuromyelitis optica: an antibody-mediated disorder of the central nervous system.
        Neurol. Res. Int. 2012; 2012460825
        • Pache F.
        • Zimmermann H.
        • Mikolajczak J.
        • Schumacher S.
        • Lacheta A.
        • Oertel F.C.
        • Bellmann-Strobl J.
        • Jarius S.
        • Wildemann B.
        • Reindl M.
        • Waldman A.
        • Soelberg K.
        • Asgari N.
        • Ringelstein M.
        • Aktas O.
        • Gross N.
        • Buttmann M.
        • Ach T.
        • Ruprecht K.
        • Paul F.
        • Brandt A.U.
        • in cooperation with the Neuromyelitis Optica Study, G.
        MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients.
        J. Neuroinflamm. 2016; 13: 282
        • Pandit L.
        • Mustafa S.
        • Uppoor R.
        • Nakashima I.
        • Takahashi T.
        • Kaneko K.
        Reversible paraspinal muscle hyperintensity in anti-MOG antibody-associated transverse myelitis.
        Neurol. Neuroimmunol. Neuroinflamm. 2018; 5: e412
        • Pearce J.M.
        Neuromyelitis optica.
        Spinal Cord. 2005; 43: 631-634
        • Pekcevik Y.
        • Mitchell C.H.
        • Mealy M.A.
        • Orman G.
        • Lee I.H.
        • Newsome S.D.
        • Thompson C.B.
        • Pardo C.A.
        • Calabresi P.A.
        • Levy M.
        • Izbudak I.
        Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging.
        Multiple Scler. 2016; 22: 302-311
        • Peschl P.
        • Bradl M.
        • Hoftberger R.
        • Berger T.
        • Reindl M.
        Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases.
        Front. Immunol. 2017; 8: 529
        • Pham-Dinh D.
        • Mattei M.G.
        • Nussbaum J.L.
        • Roussel G.
        • Pontarotti P.
        • Roeckel N.
        • Mather I.H.
        • Artzt K.
        • Lindahl K.F.
        • Dautigny A.
        Myelin/oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex.
        Proc. Natl. Acad. Sci. USA. 1993; 90: 7990-7994
        • Popescu B.F.
        • Lucchinetti C.F.
        Immunopathology: autoimmune glial diseases and differentiation from multiple sclerosis.
        Handb Clin Neurol. 2016; 133: 95-106
        • Probstel A.K.
        • Dornmair K.
        • Bittner R.
        • Sperl P.
        • Jenne D.
        • Magalhaes S.
        • Villalobos A.
        • Breithaupt C.
        • Weissert R.
        • Jacob U.
        • Krumbholz M.
        • Kuempfel T.
        • Blaschek A.
        • Stark W.
        • Gartner J.
        • Pohl D.
        • Rostasy K.
        • Weber F.
        • Forne I.
        • Khademi M.
        • Olsson T.
        • Brilot F.
        • Tantsis E.
        • Dale R.C.
        • Wekerle H.
        • Hohlfeld R.
        • Banwell B.
        • Bar-Or A.
        • Meinl E.
        • Derfuss T.
        Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis.
        Neurology. 2011; 77: 580-588
        • Ramanathan S.
        • Mohammad S.
        • Tantsis E.
        • Nguyen T.K.
        • Merheb V.
        • Fung V.S.C.
        • White O.B.
        • Broadley S.
        • Lechner-Scott J.
        • Vucic S.
        • Henderson A.P.D.
        • Barnett M.H.
        • Reddel S.W.
        • Brilot F.
        • Dale R.C.
        • Australasian, New Zealand, M.O.G.S.G.
        Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.
        J. Neurol. Neurosurg. Psychiatry. 2018; 89: 127-137
        • Ramanathan S.
        • Prelog K.
        • Barnes E.H.
        • Tantsis E.M.
        • Reddel S.W.
        • Henderson A.P.
        • Vucic S.
        • Gorman M.P.
        • Benson L.A.
        • Alper G.
        • Riney C.J.
        • Barnett M.
        • Parratt J.D.
        • Hardy T.A.
        • Leventer R.J.
        • Merheb V.
        • Nosadini M.
        • Fung V.S.
        • Brilot F.
        • Dale R.C.
        Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis.
        Multiple Scler. 2016; 22: 470-482
        • Ramanathan S.
        • Reddel S.W.
        • Henderson A.
        • Parratt J.D.
        • Barnett M.
        • Gatt P.N.
        • Merheb V.
        • Kumaran R.Y.
        • Pathmanandavel K.
        • Sinmaz N.
        • Ghadiri M.
        • Yiannikas C.
        • Vucic S.
        • Stewart G.
        • Bleasel A.F.
        • Booth D.
        • Fung V.S.
        • Dale R.C.
        • Brilot F.
        Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis.
        Neurol. Neuroimmunol. Neuroinflamm. 2014; 1: e40
        • Reindl M.
        • Linington C.
        • Brehm U.
        • Egg R.
        • Dilitz E.
        • Deisenhammer F.
        • Poewe W.
        • Berger T.
        Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study.
        Brain. 1999; 122: 2047-2056
        • Rostasy K.
        • Mader S.
        • Schanda K.
        • Huppke P.
        • Gartner J.
        • Kraus V.
        • Karenfort M.
        • Tibussek D.
        • Blaschek A.
        • Bajer-Kornek B.
        • Leitz S.
        • Schimmel M.
        • Di Pauli F.
        • Berger T.
        • Reindl M.
        Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis.
        Arch. Neurol. 2012; 69: 752-756
        • Saini H.
        • Fernandez G.
        • Kerr D.
        • Levy M.
        Differential expression of aquaporin-4 isoforms localizes with neuromyelitis optica disease activity.
        J. Neuroimmunol. 2010; 221: 68-72
        • Sato D.K.
        • Callegaro D.
        • Lana-Peixoto M.A.
        • Nakashima I.
        • Fujihara K.
        Seronegative neuromyelitis optica spectrum–the challenges on disease definition and pathogenesis.
        Arq. Neuropsiquiatr. 2014; 72: 445-450
        • Sato D.K.
        • Callegaro D.
        • Lana-Peixoto M.A.
        • Waters P.J.
        • de Haidar Jorge F.M.
        • Takahashi T.
        • Nakashima I.
        • Apostolos-Pereira S.L.
        • Talim N.
        • Simm R.F.
        • Lino A.M.
        • Misu T.
        • Leite M.I.
        • Aoki M.
        • Fujihara K.
        Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
        Neurology. 2014; 82: 474-481
        • Sepulveda M.
        • Armangue T.
        • Sola-Valls N.
        • Arrambide G.
        • Meca-Lallana J.E.
        • Oreja-Guevara C.
        • Mendibe M.
        • Alvarez de Arcaya A.
        • Aladro Y.
        • Casanova B.
        • Olascoaga J.
        • Jimenez-Huete A.
        • Fernandez-Fournier M.
        • Ramio-Torrenta L.
        • Cobo-Calvo A.
        • Vinals M.
        • de Andres C.
        • Meca-Lallana V.
        • Cervello A.
        • Calles C.
        • Rubio M.B.
        • Ramo-Tello C.
        • Caminero A.
        • Munteis E.
        • Antiguedad A.R.
        • Blanco Y.
        • Villoslada P.
        • Montalban X.
        • Graus F.
        • Saiz A.
        Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus.
        Neurol. Neuroimmunol. Neuroinflamm. 2016; 3: e225
        • Spadaro M.
        • Gerdes L.A.
        • Krumbholz M.
        • Ertl-Wagner B.
        • Thaler F.S.
        • Schuh E.
        • Metz I.
        • Blaschek A.
        • Dick A.
        • Bruck W.
        • Hohlfeld R.
        • Meinl E.
        • Kumpfel T.
        Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis.
        Neurol. Neuroimmunol. Neuroinflamm. 2016; 3: e257
        • Spadaro M.
        • Gerdes L.A.
        • Mayer M.C.
        • Ertl-Wagner B.
        • Laurent S.
        • Krumbholz M.
        • Breithaupt C.
        • Hogen T.
        • Straube A.
        • Giese A.
        • Hohlfeld R.
        • Lassmann H.
        • Meinl E.
        • Kumpfel T.
        Histopathology and clinical course of MOG-antibody-associated encephalomyelitis.
        Ann. Clin. Trans. Neurol. 2015; 2: 295-301
        • Stefferl A.
        • Brehm U.
        • Linington C.
        The myelin oligodendrocyte glycoprotein (MOG): a model for antibody-mediated demyelination in experimental autoimmune encephalomyelitis and multiple sclerosis.
        J. Neural Transm. Suppl. 2000; : 123-133
        • Stiebel-Kalish H.
        • Lotan I.
        • Brody J.
        • Chodick G.
        • Bialer O.
        • Marignier R.
        • Bach M.
        • Hellmann M.A.
        Retinal nerve fiber layer may be better preserved in MOG-IgG versus AQP4-IgG optic neuritis: a cohort study.
        PLoS One. 2017; 12e0170847
        • Wang J.J.
        • Jaunmuktane Z.
        • Mummery C.
        • Brandner S.
        • Leary S.
        • Trip S.A.
        Inflammatory demyelination without astrocyte loss in MOG antibody-positive NMOSD.
        Neurology. 2016; 87: 229-231
        • Waters P.
        • Woodhall M.
        • O'Connor K.C.
        • Reindl M.
        • Lang B.
        • Sato D.K.
        • Jurynczyk M.
        • Tackley G.
        • Rocha J.
        • Takahashi T.
        • Misu T.
        • Nakashima I.
        • Palace J.
        • Fujihara K.
        • Leite M.I.
        • Vincent A.
        MOG cell-based assay detects non-MS patients with inflammatory neurologic disease.
        Neurol. Neuroimmunol. Neuroinflamm. 2015; 2: e89
        • Waters P.J.
        • McKeon A.
        • Leite M.I.
        • Rajasekharan S.
        • Lennon V.A.
        • Villalobos A.
        • Palace J.
        • Mandrekar J.N.
        • Vincent A.
        • Bar-Or A.
        • Pittock S.J.
        Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.
        Neurology. 2012; 78 (discussion 669): 665-671
        • Weinshenker B.G.
        • Wingerchuk D.M.
        • Vukusic S.
        • Linbo L.
        • Pittock S.J.
        • Lucchinetti C.F.
        • Lennon V.A.
        Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis.
        Ann. Neurol. 2006; 59: 566-569
        • Wingerchuk D.M.
        • Banwell B.
        • Bennett J.L.
        • Cabre P.
        • Carroll W.
        • Chitnis T.
        • de Seze J.
        • Fujihara K.
        • Greenberg B.
        • Jacob A.
        • Jarius S.
        • Lana-Peixoto M.
        • Levy M.
        • Simon J.H.
        • Tenembaum S.
        • Traboulsee A.L.
        • Waters P.
        • Wellik K.E.
        • Weinshenker B.G.
        • International Panel for, N.M.O.D.
        International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
        Neurology. 2015; 85: 177-189
        • Zamvil S.S.
        • Slavin A.J.
        Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder.
        Neurol. Neuroimmunol. Neuroinflamm. 2015; 2: e62
        • Zekeridou A.
        • Lennon V.A.
        Aquaporin-4 autoimmunity.
        Neurol. Neuroimmunol. Neuroinflamm. 2015; 2: e110